


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-27 (canceled)

28 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (I):




(I)

wherein: **X** is -CHR₅-, -CHR₅-alkyl-, or -CHR₅-alkenyl-;

R₁ is selected from the group consisting of:

- R₄-CR₃-Z-R₆-alkyl,
- R₄-CR₃-Z-R₆-alkenyl,
- R₄-CR₃-Z-R₆-aryl,
- R₄-CR₃-Z-R₆-heteroaryl,
- R₄-CR₃-Z-R₆-heterocyclyl,
- R₄-CR₃-Z-H,
- R₄-NR₇-CR₃-R₆-alkyl,
- R₄-NR₇-CR₃-R₆-alkenyl,
- R₄-NR₇-CR₃-R₆-aryl,
- R₄-NR₇-CR₃-R₆-heteroaryl,
- R₄-NR₇-CR₃-R₆-heterocyclyl, and



each Z is independently $-NR_5-$, $-O-$, or $-S-$;

R_2 is selected from the group consisting of:

- hydrogen,
- alkyl,
- alkenyl,
- aryl,
- heteroaryl,
- heterocyclyl,
- alkyl-Y-alkyl,
- alkyl-Y-alkenyl,
- alkyl-Y-aryl, and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

- OH,
- halogen,
- $-N(R_5)_2$,
- $-CO-N(R_5)_2$,
- $-CO-C_{1-10}$ alkyl,
- $-CO-O-C_{1-10}$ alkyl,
- $-N_3$,
- aryl,
- heteroaryl,
- heterocyclyl,
- $-CO$ -aryl, and
- $-CO$ -heteroaryl;

each R_3 is $=O$ or $=S$;

each R_4 is independently alkyl or alkenyl, which may be interrupted by one or more $-O-$ groups;

each R_5 is independently H or C_{1-10} alkyl;

R₆ is a bond, alkyl, or alkenyl, which may be interrupted by one or more

–O– groups;

R₇ is H, C₁₋₁₀ alkyl, or arylalkyl; or when **R₄** is alkyl and **R₇** is C₁₋₁₀ alkyl, **R₄** and **R₇** can join together to form a piperidine ring;

R₈ is H or C₁₋₁₀ alkyl;


each **Y** is independently –O– or –S(O)₀₋₂;

n is 0; and

each **R** present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

29 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (II):



(II)

wherein: **X** is –CHR₅–, –CHR₅–alkyl–, or –CHR₅–alkenyl–;

R₁ is selected from the group consisting of:

–R₄–CR₃–Z–R₆–alkyl,

–R₄–CR₃–Z–R₆–alkenyl,

–R₄–CR₃–Z–R₆–aryl,

–R₄–CR₃–Z–R₆–heteroaryl,

–R₄–CR₃–Z–R₆–heterocyclyl,

–R₄–CR₃–Z–H,

-R₄-NR₇-CR₃-R₆-alkyl,
-R₄-NR₇-CR₃-R₆-alkenyl,
-R₄-NR₇-CR₃-R₆-aryl,
-R₄-NR₇-CR₃-R₆-heteroaryl,
-R₄-NR₇-CR₃-R₆-heterocyclyl, and
-R₄-NR₇-CR₃-R₈;

each **Z** is independently -NR₅-, -O-, or -S-;

R₂ is selected from the group consisting of:

-hydrogen,
-alkyl,
-alkenyl,
-aryl,
-heteroaryl,
-heterocyclyl,
-alkyl-Y-alkyl,
-alkyl-Y-alkenyl,
-alkyl-Y-aryl, and
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,
-halogen,
-N(R₅)₂,
-CO-N(R₅)₂,
-CO-C₁₋₁₀ alkyl,
-CO-O-C₁₋₁₀ alkyl,
-N₃,
-aryl,
-heteroaryl,
-heterocyclyl,
-CO-aryl, and
-CO-heteroaryl;

each **R**₃ is =O or =S;
each **R**₄ is independently alkyl or alkenyl, which may be interrupted by one or more –O– groups;
each **R**₅ is independently H or C₁₋₁₀ alkyl;
R₆ is a bond, alkyl, or alkenyl, which may be interrupted by one or more –O– groups;
R₇ is H, C₁₋₁₀ alkyl, or arylalkyl; or when **R**₄ is alkyl and **R**₇ is C₁₋₁₀ alkyl, **R**₄ and **R**₇ can join together to form a piperidine ring;
R₈ is H or C₁₋₁₀ alkyl;
each **Y** is independently –O– or –S(O)₀₋₂;
n is 0; and
each **R** present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, hydroxy, halogen, and trifluoromethyl;
or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.